Inside information: Canatu receives further reactor order from FST, validating its CNT technology for pellicle manufacturing
Canatu Plc Inside information 24 August 2026 at 11:10 a.m. EEST
Inside information: Canatu receives further reactor order from FST, validating its CNT technology for pellicle manufacturing
Canatu Plc (CANATU, Nasdaq First North Growth Market Finland) has received an order for further CNT100 SEMI reactor from Korean semiconductor company FINE SEMITECH CORPORATION (FST).
The order follows the previously announced purchase order for long-lead time items and represents the next step in the companies’ collaboration to scale the production of carbon nanotube (CNT) pellicle membranes for the semiconductor industry.
The total value of the reactor order, including the previously announced long-lead-time items order, is classified as “large” under Canatu’s disclosure policy, corresponding to a contract value of more than EUR 5 million and excluding royalties and other recurring elements. The reactor is expected to be delivered in 2027. Accordingly, while the order is expected to contribute to Canatu’s revenue already during the second half of 2026, the majority of the revenue generated from the order is expected to be recognized only in 2027.
Dr. Maximilian Slawinski, CEO of Canatu, commented:
“This reactor order demonstrates continued confidence in our unique CNT technology and reactor platform, while providing further validation of the growing market opportunity for CNT pellicles in advanced semiconductor manufacturing. It also marks another huge step towards the implementation of Canatu’s CNT Technology as a new standard for pellicles used in EUV semiconductor manufacturing. I am also very thankful for the expanding partnership with FST solidified by this milestone of the joint collaboration.”
Commercial adoption of CNT pellicle manufacturing continues
This order builds on a series of milestones in the commercialization of CNT membrane technology for pellicle manufacturing. Canatu shipped its first CNT100 SEMI reactor in September 2024. In July 2025, the reactor and associated post-processing equipment received customer approval, enabling commercial-scale manufacturing of advanced CNT-based EUV pellicles. In October 2025, Canatu granted FST a commercial production license, establishing the framework for royalty-bearing production.
Earlier in 2026, FST placed an order for long-lead time items. This reactor order represents the continuation of this commercialization pathway, expanding the customer’s manufacturing capacity of CNT pellicles.
Once commercial production using the additional reactor commences, Canatu expects to generate recurring revenues through royalties and proprietary consumables used in the CNT manufacturing process.
Additional information
Dr. Maximilian Slawinski, CEO, maximilian.slawinski@canatu.com
Mikko Vesterinen, CFO, mikko.vesterinen@canatu.com
Certified adviser
DNB Carnegie Investment Bank AB (publ), tel. +46 (0) 8 588 685 70
About Canatu
Canatu (CANATU, Nasdaq First North, Finland) is a deep technology scaleup company creating advanced carbon nanotubes (Canatu CNTs), related products, and manufacturing equipment for the semiconductor, robotics, mobility and defense, and medical diagnostics industries. Canatu partners with forerunner companies, together transforming products for better tomorrows with nano carbon.
Canatu’s versatile platform technology has broad potential applications. Its current core includes CNT membranes for extreme ultraviolet (EUV) processes in the semiconductor industry, enabling more effective manufacturing of the most advanced chips. Additionally, electrochemical sensors for medical diagnostics are in the development phase. Canatu’s patented CNT reactors and Dry Deposition by CanatuTM method yield clean and pristine CNTs. The company operates through two business models: selling CNT products directly, as well as selling CNT reactors and licensing the related technology so that customers can produce CNT products under a limited license.
Headquartered in Finland, Canatu also operates in the US, Japan and Taiwan. Founded in 2004 as a spin-off from Aalto University’s Nanomaterials Group, Canatu has 185 full-time equivalent employees representing over 35 nationalities, with nearly 20% holding or pursuing doctorates. Discover more at www.canatu.com and follow us on LinkedIn.
Forward-looking statements
Certain statements in this release are “forward-looking statements”. Forward-looking statements include statements concerning plans, assumptions, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, the Company’s competitive strengths and weaknesses, plans or goals relating to financial position, future operations and development, its business strategy and the anticipated trends in the industry and the political and legal environment in which it operates and other information that is not historical information, such as revenue growth, EBIT growth, cost savings, investments, future cash flow generation, operating profit margin, operating capital expenditure, ratio of net debt and EBIT, revenue, and operating results. In some instances, they can be identified by the use of forward-looking terminology, including the terms “believes”, “intends”, “may”, “will” or “should” or, in each case, their negative or variations on comparable terminology.
Forward-looking statements in this company announcement are based on various assumptions, many of which in turn are based on assumptions. By their very nature, forward-looking statements involve inherent risks, uncertainties and assumptions, both general and specific, and the risk exists that the predictions, forecasts, projections, plans and other forward-looking statements will not be achieved. Given these risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements. Any information, views and forward-looking statements contained in this company announcement speak only as at the date of this company announcement. Save as required by law, the Company or DNB Carnegie Investment Bank AB (publ) do not intend and do not assume any obligation to update or correct any forward-looking statement contained in this company announcement and do not undertake to publish such updates or corrections.